Skip to main content

Table 2 Changes in estimated mean levels of continuous clinical endpoints over time

From: Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes

Change in Visit Estimated mean and 95% CI Estimated mean difference from T0 and 95% CI p-value
HbA1c (%) T0 8.55(8.27;8.83)   
T1 7.16(6.88;7.44)  − 1.38 ( − 1.68; − 1.09)  < 0.0001
FBG (mg/dl) T0 186.03 (177.05;195.01)   
T1 129.5 (120.52;138.48)  − 56.53 ( − 67.17; − 45.89)  < 0.0001
BMI (Kg/m2) T0 32.9 (31.81;33.99)   
T1 30.73 (29.63;31.82)  − 2.18 ( − 2.56; − 1.79)  < 0.0001
Weight (Kg) T0 94.23 (90.75;97.72)   
T1 88.2 (84.72;91.69)  − 6.03 ( − 7.13; − 4.93) < 0.0001
SBP (mmHg) T0 135.82 (133.63;138.01)   
T1 133.06 (130.87;135.25)  − 2.76 ( − 4.08; − 1.44)  < 0.0001
DBP (mmHg) T0 79.57 (78.05;81.08)   
T1 75.72 (74.21;77.23)  − 3.85 ( − 5.02; − 2.67)  < 0.0001
Total chol (mg/dl) T0 190.33 (181.44;199.22)   
T1 172.18 (163.29;181.07)  − 18.14 ( − 23.99; − 12.3)  < 0.0001
HDL-chol (mg/dl) T0 44.84 (42.49;47.18)   
T1 47.44 (45.1;49.79) 2.61 (1.14;4.07) 0.0006
LDL-chol (mg/dl) T0 105.49 (97.87;113.12)   
T1 94.56 (86.94;102.19)  − 10.93 ( − 16.47; − 5.39) 0.0002
TG (mg/dl) T0 199.99 (181.44;218.54)   
T1 150.89 (132.35;169.44)  − 49.1 ( − 65.47; − 32.72)  < 0.0001
Non HDL-chol (mg/dl) T0 145.49 (137.11;153.87)   
T1 124.74 (116.36;133.12)  − 20.75 ( − 26.71; − 14.79) < 0.0001
  1. HbA1c Glycated haemoglobin, FBG Fasting blood glucose, SBP Systolic blood pressure, DBP Diastolic blood pressure, chol Cholesterol, HDL High-density lipoprotein, LDL Low-density lipoprotein, TG Triglycerides, 95% CI = 95% confidence intervals
  2. *Values in bold are statistically significant